Planet 13 Holdings (PLNH) Cash from Financing Activities (2021 - 2025)
Planet 13 Holdings' (PLNH) quarterly Cash from Financing Activities came in at $1.8 million in Q2 2025, up 150.55% year-on-year from $698465.9 in Q2 2024, and up 3241.74% on a QoQ basis from $52368.0 in Q1 2025.
Planet 13 Holdings (PLNH) Cash from Financing Activities (2021 - 2025) Analysis & Trends
Planet 13 Holdings (PLNH) has 5 years of Cash from Financing Activities data on file, last reported at $1.8 million in Q2 2025.
- On a quarterly basis, Cash from Financing Activities rose 150.55% year-over-year to $1.8 million in Q2 2025; TTM through Mar 2026 was $1.8 million, a 155.85% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, down 73.21% from the prior year.
- Cash from Financing Activities for Q2 2025 stood at $1.8 million, up from $52368.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for PLNH reached as high as $61.2 million in Q1 2021 and fell as low as -$3.5 million in Q2 2024.
- Historically, Cash from Financing Activities has averaged $5.3 million across 5 years, with a median of $75174.0 in 2022.
- Across the five-year window, Cash from Financing Activities soared 5929.2% in 2022 and sank 1527700.0% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at $17320.0 in 2021, then surged by 5929.2% to $1.0 million in 2022, then tumbled by 100.0% to -$3.0 in 2023, then sank by 1527700.0% to -$45834.0 in 2024, then soared by 3918.13% to $1.8 million in 2025.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $1.8 million in Q2 2025, $52368.0 in Q1 2025, and -$45834.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Planet 13 Holdings | 39.35 Mn | 23.09 Mn | 9.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 1.75 Mn |
| Mar 31, 2025 | 52,368.00 |
| Mar 31, 2025 | 52,368.00 |
| Dec 31, 2024 | -45,834.00 |
| Dec 31, 2024 | -45,834.00 |
| Sep 30, 2024 | 322,049.00 |
| Sep 30, 2024 | 322,049.00 |
| Jun 30, 2024 | -3.46 Mn |
| Jun 30, 2024 | -3.46 Mn |
| Mar 31, 2024 | 9.91 Mn |
| Mar 31, 2024 | 9.91 Mn |
| Dec 31, 2023 | -3.00 |
| Dec 31, 2023 | -3.00 |
| Jun 30, 2023 | -267,526.00 |
| Jun 30, 2023 | -267,526.00 |
| Dec 31, 2022 | 1.04 Mn |
| Dec 31, 2022 | 1.04 Mn |
| Jun 30, 2022 | 97,980.00 |
| Jun 30, 2022 | 97,980.00 |